1. Home
  2. NAMS
  3. NAMS News

Latest NewAmsterdam Pharma Company N.V. (NAMS) News on November 26, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
NAMS

GlobeNewswire

14 hours ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December

NAMS

MT Newswires

2 months ago

Newamsterdam Pharma Insider Sold Shares Worth $3,874,017, According to a Recent SEC Filing

NAMS

MT Newswires

3 months ago

Newamsterdam Pharma Insider Sold Shares Worth $453,452, According to a Recent SEC Filing

Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%
NAMS

Simply Wall St.

6 months ago

Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
NAMS

GlobeNewswire

6 months ago

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

NewAmsterdam Pharma to Host R&D Day on June 11, 2025
NAMS

GlobeNewswire

6 months ago

NewAmsterdam Pharma to Host R&D Day on June 11, 2025

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
NAMS

GlobeNewswire

6 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
NAMS

GlobeNewswire

6 months ago

NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference

NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)
NAMS

Simply Wall St.

7 months ago

NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025
NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress
NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS Congress

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors
NAMS

GlobeNewswire

7 months ago

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

8 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
NAMS

Investor's Business Daily

8 months ago

Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference
NAMS

GlobeNewswire

8 months ago

NewAmsterdam Pharma to Present at the 24th Annual Needham Virtual Healthcare Conference

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year
NAMS

Simply Wall St.

9 months ago

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Yearly Results: Here's What Analysts Are Forecasting For This Year

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
NAMS

Simply Wall St.

9 months ago

NewAmsterdam Pharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update
NAMS

GlobeNewswire

9 months ago

NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
NAMS

GlobeNewswire

9 months ago

NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease
NAMS

Simply Wall St.

9 months ago

Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) along with institutions must be dismayed after last week's 8.1% decrease

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

10 months ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference
NAMS

GlobeNewswire

10 months ago

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating
NAMS

Investor's Business Daily

a year ago

NewAmsterdam Pharma Stock Hits 90-Plus RS Rating

NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug
NAMS

Investor's Business Daily

a year ago

NewAmsterdam Pharma Soars 41% On A Surprise Benefit From Cholesterol Drug

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results
NAMS

TipRanks

a year ago

NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study
NAMS

Investor's Business Daily

a year ago

NewAmsterdam Dives — And Sacrifices A Cup Base — Despite A Winning Cholesterol Study

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 TANDEM Clinical Trial Evaluating the Fixed-Dose Combination of Obicetrapib 10 mg and Ezetimibe 10 mg in Patients with ASCVD or ASCVD Risk Factors and/or HeFH

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate
NAMS

Simply Wall St.

a year ago

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Participate in Upcoming Medical and Investor Conferences in November

Three Undervalued Small Caps In United States With Insider Buying To Consider
NAMS

Simply Wall St.

a year ago

Three Undervalued Small Caps In United States With Insider Buying To Consider

Insider Buying Highlights These 3 Undervalued Small Caps In United States
NAMS

Simply Wall St.

a year ago

Insider Buying Highlights These 3 Undervalued Small Caps In United States

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NAMS

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/02/2024

3 Undervalued Small Caps In United States With Insider Buying
NAMS

Simply Wall St.

a year ago

3 Undervalued Small Caps In United States With Insider Buying

While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership
NAMS

Simply Wall St.

a year ago

While institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownership

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September

NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations
NAMS

Simply Wall St.

a year ago

NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma (NASDAQ:NAMS) Is In A Good Position To Deliver On Growth Plans
NAMS

Simply Wall St.

a year ago

NewAmsterdam Pharma (NASDAQ:NAMS) Is In A Good Position To Deliver On Growth Plans

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations
NAMS

Investor's Business Daily

a year ago

NewAmsterdam Touts Cholesterol Drug Success, But Results Trail Analysts' Expectations

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku
NAMS

CNW Group

a year ago

Hyundai Motor Presents Its First Film 'Night Fishing' in Collaboration with K-Movie Star Son Sukku

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse
NAMS

PR Newswire

a year ago

IMAGO AIOS Prime Clinches Red Dot Award for 2024, Expands US Footprint with New Boston Warehouse

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store
NAMS

Business Wire

a year ago

Seibu Ikebukuro Main Store Slated for Summer 2025 Grand Re-opening as a New Department Store

New Zealand scraps plan to tax livestock burps, farts
NAMS

AFP

a year ago

New Zealand scraps plan to tax livestock burps, farts

NAMS

Business Wire

a year ago

InnoCare Announces Clearance of Clinical Trial of TYK2 Inhibitor ICP-332 by U.S. FDA

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility
NAMS

The Wall Street Journal

a year ago

ECB’s Lagarde Sees Multi-Meeting Rate Holds A Possibility

UK Unemployment Rises in Sign Inflationary Pressures Cool
NAMS

Bloomberg

a year ago

UK Unemployment Rises in Sign Inflationary Pressures Cool

Insider-Owned Growth Companies On The Chinese Exchange In June 2024
NAMS

Simply Wall St.

a year ago

Insider-Owned Growth Companies On The Chinese Exchange In June 2024

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NAMS

GlobeNewswire

a year ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings

NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)
NAMS

Simply Wall St.

2 years ago

NewAmsterdam Pharma First Quarter 2024 Earnings: US$1.06 loss per share (vs US$0.50 loss in 1Q 2023)

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations
NAMS

Simply Wall St.

2 years ago

NewAmsterdam Pharma Full Year 2023 Earnings: Revenues Miss Expectations

NAMS

GuruFocus.com

2 years ago

NewAmsterdam Pharma Co NV (NAMS) Faces Net Loss in 2023 Despite Clinical Progress

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants

NAMS

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Hub Group Inc Earnings Call

NAMS

Morningstar Research

2 years ago

Analyst Report: Hub Group, Inc.

Hub Group sees Q4 revenue fall 23% year-over-year to $985M
NAMS

FreightWaves

2 years ago

Hub Group sees Q4 revenue fall 23% year-over-year to $985M

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
NAMS

GlobeNewswire

2 years ago

NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024
NAMS

GlobeNewswire

2 years ago

Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30
NAMS

CNW Group

2 years ago

SmallRig Founder and Chairman Zhou Yang Recognized as One of Forbes China's Inaugural Globalization Innovators Top30

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit
NAMS

Barrons.com

2 years ago

SoFi Stock Soars After Company Posts First-Ever Quarterly Profit

United Arab Emirates Smart Manufacturing Market Analysis Showcases Growth Trends and Opportunities up to 2030
NAMS

GlobeNewswire

2 years ago

United Arab Emirates Smart Manufacturing Market Analysis Showcases Growth Trends and Opportunities up to 2030

Hilltop Holdings Inc. (NYSE:HTH) Q4 2023 Earnings Call Transcript
NAMS

Insider Monkey

2 years ago

Hilltop Holdings Inc. (NYSE:HTH) Q4 2023 Earnings Call Transcript

Sensient Announces Conference Call
NAMS

Business Wire

2 years ago

Sensient Announces Conference Call

AmEx 4Q profits jump 23% as cardmembers carry heftier balances
NAMS

Associated Press Finance

2 years ago

AmEx 4Q profits jump 23% as cardmembers carry heftier balances

Afya Limited Announces Medical Seats Increase in FIP Guanambi
NAMS

Business Wire

2 years ago

Afya Limited Announces Medical Seats Increase in FIP Guanambi

Realty Income (O) Expands With Spirit Realty Capital Merger
NAMS

Zacks

2 years ago

Realty Income (O) Expands With Spirit Realty Capital Merger

Playtika (PLTK) Loses -13.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NAMS

Zacks

2 years ago

Playtika (PLTK) Loses -13.82% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Is Visa (V) Poised for Q1 Earnings Beat on Transactions Growth?
NAMS

Zacks

2 years ago

Is Visa (V) Poised for Q1 Earnings Beat on Transactions Growth?

Share on Social Networks: